Device manufacturers will be displaying their latest technologies at the 2023 Society of Cardiovascular Computed Tomography Annual Scientific Meeting (SCCT2023) being held in Boston from July 27 - 30. The industry’s top computed tomography (CT) companies have chosen SCCT2023 as a key platform to inform and connect with physicians about their products and services. SCCT’s industry partners — including Cleerly, Inc., GE Healthcare and Siemens Healthineers — will showcase their latest technologies.
At the meeting, GE Healthcare will be showcasing new technologies in the field, like the Revolution Apex Platform and the CardioGraphe, as well as presenting the Financial Impact of Cardiac CT for the Cardiovascular Service Line.
Using cutting-edge technology, the Revolution Apex Platform aims to keep radiology departments ahead of the curve with a high-performance CT imaging system. "What's nice about the Apex Platform is that evolution is done in that platform and that you can easily bring your technologists, your nurses, your radiologists on a higher level without moving too much on the system," stated Johan de Mey, MD, PhD.
The CardioGraphe is another CT system that provides exceptional diagnostic image quality in an efficient manner with fast temporal resolution. The technology is compact with a user interface optimized for repeatability and usability.
In regards to their partnership with SCCT, GE Healthcare stated that, “With SCCT as a cornerstone of our business strategy, GE Healthcare is driving advancements in the field of cardiovascular imaging, equipping healthcare providers with the tools they need to deliver superior patient care. By harnessing the power of innovation, technology, and collaboration, we are shaping the future of cardiac CT and driving transformative change in the field of cardiovascular medicine.”
For more information stop by the GE Healthcare booth (#109).
Join the Siemens Healthineers booth (#213) for a lunch symposium to hear from users and learn about the NAEOTOM Alpha with Quantum Technology. The NAEOTOM Alpha with Quantum Technology is the world's first photon counting CT. It offers high-resolution images, spectral information in every scan, and improved contrast at lower noise. By offering intrinsic spectral imaging independent of scan speed and of temporal or spatial resolution, NAEOTOM Alpha redefines which patient populations can be addressed with cardiac CT – even those with heavy calcification or stents. It brings spectral imaging to the coronary vessels and benefits from impressive details for small structures.
Siemens Healthineers will also be promoting their whitepaper “Dual Source CT in cardiac imaging: with a world of applications to explore, how can we help you tap into the full potential of Dual Source CT?”.
"Siemens Healthineers shares SCCT’s mission to improve health outcomes through effective use of cardiovascular CT,” Siemens Healthineers stated, “Our innovative technologies across a broad portfolio of CT scanners are designed to optimize workflow efficiency and provide consistent, high-quality images. As the role of cardiovascular CT expands, we strive to empower customers in every setting – from outpatient centers to academic and research hospitals – to offer high quality cardiovascular imaging.”
Another manufacturer that will be in attendance, Cleerly Inc., “measures what actually causes heart attacks, atherosclerosis (plaque), rather than risk factors and indirect markers. The goal of the analysis is to examine the burden and type of coronary plaque at a microscopic level and truly identify a person’s level of coronary artery disease (CAD), while also looking at stenosis, which helps guide clinical decision making.”
“The results have rapid turnaround time,” Cleerly expressed, “being available within minutes to hours, and they are easy for imagers, clinicians and patients alike to read and interpret without needing separate sets of test results.”
At SCCT2023, Cleerly will be presenting their AI-enabled coronary computerized tomography angiography (CCTA) analysis which provides physicians with information that traditional technology is not able to glean. “The FDA-cleared AI algorithms non-invasively generate a 3D model of a patient’s coronary arteries, identify their lumen and vessel walls, locate and quantify stenoses, as well as identify, quantify and categorize plaque,” Cleerly shared.
“Cleerly’s personalized care pathway for heart attack prevention, backed by nearly two decades of clinical research, focuses on measuring, characterizing, and tracking atherosclerosis instead of searching for and relying on less useful indirect markers of heart disease. The care pathway provides cardiovascular care with a closed-loop, step-by-step approach for early diagnosis, informed decision-making, and personalized treatment and tracking of CAD, with the ultimate goal of empowering physicians with the right insights to prevent heart attacks for hundreds of thousands in the U.S and around the world.”
For more information on the care pathway visit the Cleerly, Inc. website.
“We’re looking forward to attending SCCT 2023 alongside other leaders in the cardiovascular computed tomography industry,” said James K. Min, MD, FACC, FESC, MSCCT, founder and CEO of Cleerly. “The work we are doing at Cleerly to transform cardiovascular care and personalize heart disease evaluation leveraging AI technologies was founded on the scientific concepts continuously embraced by SCCT. The Society has a great impact both on Cleerly’s efforts and the cardiology community through their ongoing advocation for access, research, education, and clinical excellence.”
For more information: www.scct.org